

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Applicants: Thomas M. DiMauro, Mohamed Attawia, Hassan Serhan, Martin A. Reynolds, Melissa Grace, Sudhakar Kadiyala, David Urbahns, Scott Bruder, Gregory Collins, Laura J. Brown, Jeff Geesin, Pamela L. Plouhar, Catherine Smith and John Siekierka

Application No.: 10/630,227 Group: 1647

Filed: July 30, 2003 Examiner: Shulamith H. Shafer

Confirmation No.: 8291

For: TRANS-CAPSULAR ADMINISTRATION OF HIGH SPECIFICITY CYTOKINE INHIBITORS INTO ORTHOPEDIC JOINTS

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or is being facsimile transmitted to the United States Patent and Trademark Office on:

5-14-07

Date

*Amy Comeau*

Signature

*Amy Comeau*

Typed or printed name of person signing certificate

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop After Final  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is submitted:

under 37 CFR 1.97(b), or  
(Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).

under 37 CFR 1.97(c) together with either:  
 a Statement under 37 CFR 1.97(e), as checked below, or  
 a \$180.00 fee under 37 CFR 1.17(p), or  
(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first) **05/16/2007 M6EBREM1 00000040 10630227 180.00 OP**

under 37 CFR 1.97(d) together with:  
 a Statement under 37 CFR 1.97(e), as checked below, and  
 a \$180.00 fee under 37 CFR 1.17(p), or  
(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee) **180.00 OP**

under 37 CFR 1.97(i):  
Applicant requests that the IDS and cited reference(s) be placed in the application file.  
(Filed after payment of issue fee)

Statement Under 37 CFR 1.97(e)

- Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)

*Applies to original applications (other than design) filed on or after May 29, 2000*

- Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.
- Enclosed herewith is form PTO-1449:
  - Copies of the cited references (C124-C127) are enclosed.
    - Copies of issued U.S. patents and published U.S. applications are not required and are not being provided.
  - Copies of the cited references are enclosed except those entered in prior application, U.S. Application No. [ ], to which priority under 35 U.S.C. 120 is claimed. **[OPTIONAL]** [The earlier application contains copies of the cited references.]
  - The listed references were cited in the enclosed International Search Report in a counterpart foreign application.
  - The “concise explanation” requirement (non-English references) for reference(s) [ ] under 37 CFR 1.98(a)(3) is satisfied by:
    - the explanation provided on the attached sheet.
    - the explanation provided in the Specification.
    - submission of the enclosed International Search Report.
    - submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.
    - the enclosed English language abstract.

Applicant requests that the following non-published pending applications be considered:  
*(Affix a label or apply the stamp "Non-Published IDS Reference - Do Not Scan" to the front of each unpublished pending appl'n.)*

Examiner's  
Initials

\_\_\_\_ U.S. Patent Application No. [ ], by [inventor(s)], filed [ ], Docket No.: [ ]  
 \_\_\_\_ U.S. Patent Application No. [ ], by [inventor(s)], filed [ ], Docket No.: [ ]  
 \_\_\_\_ U.S. Patent Application No. [ ], by [inventor(s)], filed [ ], Docket No.: [ ]

Examiner

Date

A copy of each above-cited application, including the current claims, is enclosed, except any application filed on or after June 30, 2003, which has been scanned into the PTO's Image File Wrapper (IFW) system and is available to the examiner.

A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [ ], to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.

Method of payment:

A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.

Please charge Deposit Account 08-0380 in the amount of \$[ ]. A copy of this Statement is enclosed.

Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By Deirdre E. Sanders

Deirdre E. Sanders

Registration No. 42,122

Telephone: (978) 341-0036

Facsimile: (978) 341-0136

Concord, MA 01742-9133

Dated: May 14, 2007

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 3518.1015-000	APPLICATION NO. 10/630,227
<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION</b>		FIRST NAMED INVENTOR Thomas M. DiMauro	
May 14, 2007  (Use several sheets if necessary)		EXAMINER Shulamith H. Shafer	FILING DATE July 30, 2003
		CONFIRMATION NO. 8291	GROUP 1647



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
C124	Ohno, K. and Oshita, S., "Transdiscal Lumbar Sympathetic Block: A New Technique for a Chemical Sympathectomy," <i>Anesth. Analg.</i> , 85:1312-1316 (1997).	
C125	Tanny, G.B. <i>et al.</i> , "Improved Filtration Technique for Concentrating and Harvesting Bacteria," <i>Appl. Environ. Microbiol.</i> , 40(2):269-273 (1980).	
C126	Raucci, A. <i>et al.</i> , "Activation of the ERK1/2 and p38 Mitogen-Activated Protein Kinase Pathways Mediates Fibroblast Growth Factor-Induced Growth Arrest of Chondrocytes," <i>J. Biol. Chem.</i> , 279(3):1747-1756 (2004).	
C127	Marriott, J.B. <i>et al.</i> , "CC-3052: A Water-Soluble Analog of Thalidomide and Potent Inhibitor of Activation-Induced TNF- $\alpha$ Production," <i>J. Immunol.</i> , 161:4236-4243 (1998).	

EXAMINER	DATE CONSIDERED
----------	-----------------